Month: June 2026

Introduction and Objective: While closed-loop (CL) technology has transformed outpatient diabetes care, evidence in acute settings is limited. This systematic review and meta-analysis (PROSPERO: CRD420251133486) evaluated the safety, efficacy, and implementation of closed-loop technology in acute care.Methods: Eligible studies included adults managed with CL in acute care reporting glycaemic, safety, and implementation outcomes compared with […]

Introduction and Objective: Diabetes Mellitus is strongly associated with vascular complications. While molecular mechanisms of hyperglycemia-induced vascular dysfunction have been extensively studied, the organization of mechanical forces within endothelial monolayers under sustained hyperglycemia remains poorly defined. We investigated whether prolonged hyperglycemia alters endothelial force organization over time.Methods: Human Umbilical Vein Endothelial Cells were cultured in […]

Introduction and Objective: MASLD prevalence has increased to ~38% globally, with over 65% of people with MASLD having concomitant T2DM. This study evaluated whether combining dorzagliatin (glucokinase activator) and resmetirom (THR-β agonist) provides synergistic metabolic and hepatic benefits in a mouse model of MASLD.Methods: Male DIO mice with confirmed MASLD were randomized to receive dorzagliatin, […]

Introduction and Objective: Early-onset type 2 diabetes (T2D) is associated with a more adverse cardiometabolic profile and increased cardiovascular (CV) risk. We aimed to characterize cardiovascular risk and subclinical atherosclerosis in young adults with T2D participating in the YOUNG DIABETES program.Methods: Observational study including individuals with T2D diagnosed at ≤50 years and current age ≤55 […]

Introduction and Objective: Metabolic Associated Steatotic Liver Disease (MASLD) frequently coexists with type 2 diabetes mellitus (T2DM) and obesity and represents a major unmet clinical need, particularly with respect to therapies that improve both hepatic and metabolic outcomes. Comparative data between saroglitazar (SARO) and dapagliflozin (DAPA) in MASLD are limited.Methods: A 24-week, prospective, multicenter, open-label, […]

Introduction and Objective: Diabetes duration is considered a primary risk factor, yet some long-standing diabetics remain complication-free while recent-onset patients develop rapid damage. We investigated whether metabolic profile (triglycerides, BMI) could override traditional duration-complication relationships in community-based type 2 diabetes.Methods: Analysis of 400 T2DM patients stratified by duration (<5y n=142, 5-10y n=158, >10y n=100) and […]

Introduction and Objective: AT7687 is a novel GIP receptor (GIPR) peptide antagonist being developed for weight management and cardiometabolic disease. Cagrilintide is a dual amylin and calcitonin receptor (CTR) agonist with established weight-lowering efficacy. To assess the therapeutic potential of combining GIPR antagonism with amylin/CTR agonism, a chronic study was conducted in non-human primates (NHPs).Methods: […]

Introduction and Objective: Guideline-directed medical therapy (GDMT) improves outcomes in people with type 2 diabetes (T2D) and chronic kidney disease (CKD) but remains underused, possibly due to low CKD screening rates. This study evaluated screening and GDMT prescribing patterns in people with T2D with and without CKD.Methods: We performed a retrospective analysis of active patients […]

Introduction and Objective: Gestational diabetes mellitus (GDM) affects ~12% of pregnancies and is associated with maternal and offspring perinatal complications and long-term metabolic risk. We assessed GDM-related knowledge gaps, perceptions, and support needs among women aged 20-49 years to inform seamless support across preconception, pregnancy, and postpartum periods.Methods: A nationwide cross-sectional web survey included women […]

Introduction and Objective: Circulating microRNAs (miRNAs) regulate metabolic and inflammatory pathways and may reflect genetic risk of type 2 diabetes (T2D) and renal failure (RF), captured through family history. Whether circulating microRNAs capture familial risk better than clinical characteristics is currently unknown.Methods: This cross-sectional design assessed a discovery subset (n=81) from a historical 2×2 factorial […]